AIM ImmunoTech宣布按市场定价265万美元融资

2026-06-09 21:54

AIM ImmunoTech (AIM) on Tuesday said it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million.
The offering is expected to close on or about June 10, 2026.
AIM -19.5% at $0.43.
In the registered direct offering, the company will issue and sell 2.55M shares of common stock, par value $0.001, at a purchase price of $0.5189 per share.
In addition, in a concurrent private placement, the company will issue and sell an aggregate of 2.55M unregistered shares of common stock at the per share purchase price and unregistered Class J warrants to purchase up to 10.21M shares of common stock.
The Class J Warrants will have an exercise price of $0.5189 per share, will be exercisable subject to stockholder approval, and will expire five years from the initial exercise date.
The company intends to use the net proceeds from the offering for (i) the manufacture of clinical drug supply, (ii) the company’s current clinical trial activities, (iii) the company’s planned Phase 3 clinical trial activities, and (iv) working capital purposes.
Press release

More on AIM ImmunoTech